Signaling Pathway
Prolgolimab (BCD-100) is a human IgG1 monoclonal antibody targeting the PD-1 receptor, incorporating an Fc region modified with the 'LALA' mutation to silence effector functions. This antibody is utilized in research focused on advanced melanoma, providing a valuable tool for investigating the immunological pathways involved in tumor progression and response to therapy.
重要通知：仅供研究使用。我们不向患者销售。
| Discription | Prolgolimab (BCD-100) is a human IgG1 monoclonal antibody targeting the PD-1 receptor, incorporating an Fc region modified with the 'LALA' mutation to silence effector functions. This antibody is utilized in research focused on advanced melanoma, providing a valuable tool for investigating the immunological pathways involved in tumor progression and response to therapy. |
||
|---|---|---|---|
| Targets |
|
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2
